Spark Biomedical Has Been Issued New CMS Codes for Transcutaneous Auricular Neurostimulation (tAN®) Therapy via Sparrow Ascent
28. August 2024 09:38 ET
|
Spark Biomedical
Dallas, TX, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Dallas, TX [August 2024] – Spark Biomedical, Inc., a leader in non-invasive neurostimulation technology, has been issued two unique Healthcare Common...
Behind the Scenes of Medical Innovation: Spark Biomedical launches new web series ‘Spark a Conversation’
01. Juli 2024 09:48 ET
|
Spark Biomedical
Dallas, TX, July 01, 2024 (GLOBE NEWSWIRE) -- For as long as there has been opioid use disorder, there have only been two solutions: cold turkey or more drugs. The founders of Spark Biomedical...
Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute
29. August 2023 14:52 ET
|
Spark Biomedical
DALLAS, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aug. 29, 2023 — Spark Biomedical, Inc., a Dallas-based pioneer in wearable neurostimulation technology, was awarded a $1.15M Phase II grant to...
Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome
03. März 2022 11:22 ET
|
Spark Biomedical
Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...
Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services, Eric D. Hargan, to help make novel opioid withdrawal treatment more accessible and affordable for patients
04. November 2021 10:25 ET
|
Spark Biomedical
Dallas, TX, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc, a leader in wearable neurostimulation for opioid withdrawal relief, today announced the Company will join forces with Eric D....
Spark Biomedical Receives FDA Breakthrough Device Designation for Infant Transcutaneous Auricular Neurostimulation (tAN™) Device, The Roo™ System
15. Dezember 2020 14:14 ET
|
Spark Biomedical
Dallas, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Roo System: a...